Making the case for precompetitive clinical development Chris Cain BriefCommunication Pages: 562 - 562
BH3 interacting domain death agonist (BID); caspase recruitment domain family member 4 (CARD4; NOD1) BriefCommunication Pages: 563 - 563
Histone methyltransferase DOT1L (DOT1L); myeloid-lymphoid or mixed-lineage leukemia translocated to 3 (MLLT3; AF9) BriefCommunication Pages: 565 - 565
Poly(ADP-ribose) polymerase (PARP); breast cancer 2 early onset (BRCA2) BriefCommunication Pages: 568 - 568
Lysophosphatidic acid receptor 1 (LPAR1; EDG2; LPA1); LPAR3 (EDG7; LPA3) BriefCommunication Pages: 571 - 571
CXC chemokine receptor 4 (CXCR4; NPY3R); CC chemokine receptor 5 (CCR5; CD195) BriefCommunication Pages: 574 - 574
Protein phosphatase 1 regulatory subunit 3C (PPP1R3C; PTG); epilepsy progressive myoclonus type 2A Lafora disease (laforin; EPM2A); NHL repeat containing 1 (NHLRC1; EPM2B) BriefCommunication Pages: 580 - 580
Nicotinic acetylcholine receptor (nAchR)-targeted micelles for drug delivery across the blood brain barrier (BBB) BriefCommunication Pages: 584 - 584
Transplantable, recellularized arterial graft using decellularized blood vessels BriefCommunication Pages: 585 - 585